A Multicenter, Open-label, Single-sequence Cross-over Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension Switching From an Oral Stable Dose of Selexipag
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Selexipag (Primary) ; Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 27 Jul 2017 Planned initiation date changed from 31 Jul 2017 to 1 Oct 2017.
- 30 Jun 2017 Planned initiation date changed from 28 Jun 2017 to 31 Jul 2017.
- 21 Jun 2017 New trial record